Payment overview · 2025
General Payments
$956.12
47 reported records · 11 companies
Healthcare provider profile · identity verified
Roberto Bermudez, MD
Allopathic & Osteopathic Physicians|Family Medicine · HOMESTEAD, FL · NPI 1780781138
Verified facts
What the public records show
CMS Open Payments records show Roberto Bermudez, MD received $956.12 in general payments during 2025 across 47 reported records.
AstraZeneca Pharmaceuticals LP accounted for 45.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 326 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $436.81 | 45.7% | 17 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $241.23 | 25.2% | 17 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $47.52 | 5.0% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $40.19 | 4.2% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $38.23 | 4.0% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $30.99 | 3.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $28.75 | 3.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $27.67 | 2.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.06 | 2.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $21.82 | 2.3% | 1 | 2025 |
| Access Pro Medical, LLC | Unresolved — no canonical attribution shown | $19.85 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $956.12 | 47 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $226.57 | 10 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $191.78 | 15 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $153.98 | 13 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $57.55 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $51.81 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $49.45 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $40.19 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $38.23 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $30.99 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $27.67 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $24.44 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $24.44 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $21.82 | 1 | 2025 |
Source payment records
|
|||||
| MATRIDERM Normalized: matriderm |
Device | Access Pro Medical, LLC | $19.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 326 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 139 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
326 | 69 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
139 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 506 | 133 |
| Omeprazole | Omeprazole | 367 | 82 |
| Losartan Potassium | Losartan Potassium | 360 | 100 |
| Farxiga | Dapagliflozin Propanediol | 326 | 69 |
| Amlodipine Besylate | Amlodipine Besylate | 307 | 76 |
| Meloxicam | Meloxicam | 263 | 71 |
| Metoprolol Succinate | Metoprolol Succinate | 251 | 56 |
| Gabapentin | Gabapentin | 249 | 66 |
| Metformin Hcl | Metformin Hcl | 214 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 185 | 46 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 182 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 177 | 39 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 163 | 42 |
| Levothyroxine Sodium | Levothyroxine Sodium | 161 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 154 | 58 |
| Ozempic | Semaglutide | 139 | 22 |
| Vascepa | Icosapent Ethyl | 135 | 33 |
| Montelukast Sodium | Montelukast Sodium | 124 | 28 |
| Famotidine | Famotidine | 119 | 33 |
| Ezetimibe | Ezetimibe | 114 | 26 |
| Prednisone | Prednisone | 112 | 56 |
| Azithromycin | Azithromycin | 108 | 63 |
| Eliquis | Apixaban | 108 | 21 |
| Ibuprofen | Ibuprofen | 104 | 25 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 98 | 33 |
| Tizanidine Hcl | Tizanidine Hcl | 95 | 37 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 94 | 19 |
| Alendronate Sodium | Alendronate Sodium | 89 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 89 | 21 |
| Trazodone Hcl | Trazodone Hcl | 89 | 22 |
| Carvedilol | Carvedilol | 86 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 83 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 82 | 24 |
| Allopurinol | Allopurinol | 81 | 22 |
| Lisinopril | Lisinopril | 79 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 72 | 16 |
| Folic Acid | Folic Acid | 71 | 20 |
| Xarelto | Rivaroxaban | 70 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 60 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 57 | 19 |
| Donepezil Hcl | Donepezil Hcl | 57 | 14 |
| Sucralfate | Sucralfate | 57 | 12 |
| Lactulose | Lactulose | 56 | 29 |
| Clonidine Hcl | Clonidine Hcl | 55 | 13 |
| Memantine Hcl | Memantine Hcl | 54 | suppressed |
| Entresto | Sacubitril/Valsartan | 52 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | 12 |
| Mirtazapine | Mirtazapine | 52 | 12 |
| Nifedipine Er | Nifedipine | 52 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 49 | 12 |
| Valsartan | Valsartan | 49 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 46 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 45 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 45 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 45 | 12 |
| Bupropion Xl | Bupropion Hcl | 39 | suppressed |
| Rybelsus | Semaglutide | 39 | suppressed |
| Finasteride | Finasteride | 38 | suppressed |
| Furosemide | Furosemide | 38 | 15 |
| Sildenafil Citrate | Sildenafil Citrate | 38 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 37 | suppressed |
| Tradjenta | Linagliptin | 36 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 35 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Celecoxib | Celecoxib | 33 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | 14 |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 31 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | suppressed |
| Linzess | Linaclotide | 30 | suppressed |
| Potassium Chloride | Potassium Chloride | 29 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 28 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Ciclopirox | Ciclopirox | 26 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | suppressed |
| Bumetanide | Bumetanide | 25 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 23 | 17 |
| Jardiance | Empagliflozin | 23 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Repatha Sureclick | Evolocumab | 23 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 23 | suppressed |
| Benzonatate | Benzonatate | 22 | 14 |
| Dapagliflozin | Dapagliflozin Propanediol | 22 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | 11 |
| Levemir Flexpen | Insulin Detemir | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 13 |
| Olanzapine | Olanzapine | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 12 |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 18 | suppressed |
| Febuxostat | Febuxostat | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Jentadueto Xr | Linagliptin/Metformin Hcl | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Promethazine-Dm | Promethazine/Dextromethorphan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $956.12 · 47 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, KRYSTEXXA, Korlym, LEQVIO, MATRIDERM, OTEZLA, Ozempic, REPATHA, Rybelsus, UBRELVY, ZORYVE | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error